Lynch Syndrome Carriers Have Two-Fold Increased Risk of Prostate Cancer

This article originally appeared here.
Share this content:
Risk of Prostate Cancer Quantified for Lynch Syndrome
Risk of Prostate Cancer Quantified for Lynch Syndrome

(HealthDay News) -- Lynch syndrome carriers have about a two-fold increased risk of prostate cancer, according to a study published online March 25 in the Journal of Clinical Oncology.

To quantify prostate cancer risk in Lynch syndrome, Victoria M. Raymond, from the University of Michigan in Ann Arbor, and colleagues reviewed the cancer histories of probands and their relatives (first- through fourth-degree) for 198 independent mutation-positive Lynch syndrome families, which included 4,127 men.

The researchers identified 97 cases of prostate cancer. Prostate cancer was diagnosed at a median age of 65 years, with 11.53 percent of cases diagnosed before the age of 50 years. At age 60 years, the cumulative risk of prostate cancer was 6.3 percent, compared with a population risk of 2.59 percent. The corresponding risks at age 80 years were 30.0 and 17.84 percent, respectively. Among carriers, the overall hazard ratio for prostate cancer was 1.99.

"Our finding that Lynch syndrome is associated with an increased risk of prostate cancer is clinically valuable for patients and clinicians when weighing risks and benefits of screening, and we suggest that prostate cancer screening be offered to this high-risk group," the authors write.

Several authors disclosed financial ties to the biotechnology industry.

Full Text

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs